Posted 5/11/2015 8:53 AM (GMT -8)
No, it is not covered and costs about $4000. The company has an assistance program.
It's potential use (and a similar test called Prolaris) is for patients with a negative biopsy and remaining suspicion, or for guys on an AS program. It's been used to predict recurrence after RP, although Decipher is better validated for that.
For most guys, it will tell them what they already know from PSA, Gleason score, and stage. For a few, it will tell them that they are at enhanced or lower genomic risk than it seems.
I don't think it's worth the cost, but I know a few guys who got it. You can probably read patient experiences by typing it in the search bar.